VivoSeq
Other

Menopausal Syndrome

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Menopausal Syndrome is an early-stage landscape with 0 programs across 1 company. The most active players are Unimed Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

U

Unimed Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Unknown status3 · 43%
Completed3 · 43%
Not yet recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

A Real-world Clinical Study on the Treatment of Menopausal Syndrome With Liuwei Dihuang Pills
Not yet recruiting·CChina Academy of Chinese Medical Sciences·N/A·NCT06874738·1,000 enrolled
Comparison Study for Perimenopausal Syndrome With Chinese Herbal Medicine
Completed·HHong Kong Baptist University·N/A·NCT05266079·100 enrolled
A Randomized, Double-Blind, Parallel, Non-Inferiority, Multicenter Trial Evaluate the Efficacy and Safety of UNCNT Compared to MELSMON in Female With Menopausal Syndrome
Completed·UUnimed Pharmaceuticals·Phase 3·NCT01931748·104 enrolled
Clinical Efficacy of Qingxin Zishen Decoction in Treating Menopausal Syndrome and Neuroendocrine Mechanism of Regulating KNDy Neurons
Completed·—·N/A·NCT06132620·60 enrolled
RCT on the Treatment of Menopausal Syndrome With Chinese Medicine
Unknown status·—·Phase 2·NCT06074809·78 enrolled
A Muticenter Clinical Study of Chinese Herbal Compound TJAOA102 in Alleviating Menopausal Syndrome
Unknown status·TTongji Hospital·Phase 1·NCT05522621·100 enrolled
QXZS in Menopausal Syndrome Based on 16S rRNA Sequencing Technology
Unknown status·—·N/A·NCT06143696·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)